• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Ideaya Biosciences(IDYA.US)

Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec12
GSK to Terminate Collaboration and License Agreement with IDEAYA Biosciences
21:37
Citi Analyst Maintains Buy Rating on Ideaya Biosciences
15:57
Dec11
IDEAYA Biosciences Completes Patient Enrollment for darovasertib and crizotinib Therapy Clinical Trial in Metastatic Uveal Melanoma
11:01
Dec10
IDEAYA Biosciences Inc Submits IDE574 IND and Plans First Phase Trial
11:02
Dec5
IDEAYA Biosciences and Biocytogen Pharmaceuticals Obtain FDA Approval for IDE034 IND Application
00:00
Nov12
Mizuho Raises IDEAYA Biosciences Price Target to $46
14:29

Schedules & Filings

Schedules
Filings
Nov4
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 207.83 M, Net Income 119.24 M, EPS 1.33

Aug5
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -77.49 M, EPS -0.8758

May6
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -72.18 M, EPS -0.8168

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
10.760
+162.44%
+6.680
ANGH
3.868
+66.74%
+1.548
ESHA
22.250
+54.73%
+7.870
SIDU
4.005
+50.00%
+1.335
NCL
0.2774
+42.99%
+0.084
RDACR
0.2493
+31.21%
+0.059
ESHAR
0.2216
+30.35%
+0.052
VNDA
8.905
+26.67%
+1.880
ORIS
1.540
+26.23%
+0.320
ULY
3.475
+25.91%
+0.715
View More